Eloxx Pharmaceuticals, Inc. (ELOX) — 8-K Filings
All 8-K filings from Eloxx Pharmaceuticals, Inc.. Browse 6 Current Event Report reports with AI-powered summaries and risk analysis.
8-K Filings (6)
-
Eloxx Pharmaceuticals Reports Board and Compensation Changes
— Aug 12, 2025 Risk: medium
Eloxx Pharmaceuticals, Inc. announced on August 6, 2025, a change in its board of directors and executive compensation arrangements. The filing details the depa -
Eloxx Pharmaceuticals Board Changes
— Oct 17, 2024 Risk: medium
Eloxx Pharmaceuticals, Inc. announced on October 16, 2024, a change in its board of directors. Specifically, Dr. Jonathan G. Drachman has been appointed as a ne -
Eloxx Pharmaceuticals Secures Funding via Convertible Notes
— Jul 16, 2024 Risk: medium
On July 10, 2024, Eloxx Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Convertible Senior Secured Promissory Note Purchase A -
Eloxx Pharmaceuticals Board Changes
— Mar 29, 2024 Risk: low
Eloxx Pharmaceuticals, Inc. announced on March 25, 2024, a change in its board of directors. Specifically, Dr. Jonathan G. W. Smith has resigned from his positi -
Eloxx Pharmaceuticals Enters Material Definitive Agreement
— Mar 14, 2024 Risk: medium
On March 11, 2024, Eloxx Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company, formerly known as Sevion Therapeutics, Inc., is incorp -
Eloxx Pharma Sells Unregistered Equity, Raising Capital
— Jan 9, 2024
On January 9, 2024, Eloxx Pharmaceuticals, Inc. entered into a material definitive agreement for an unregistered sale of equity securities. This means the compa
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX